Stereotactic Radiotherapy for Breast Cancer Metastases
Author Information
Author(s): Fabian Alexander, Buergy Daniel, Weykamp Fabian, Hörner-Rieber Juliane, Bernhardt Denise, Boda-Heggemann Judit, Pazos Montserrat, Mehrhof Nora, Kaul David, Bicu Alicia S., Badra Eugenia Vlaskou, Rogers Susanne, Janssen Stefan, Hemmatazad Hossein, Hintelmann Katharina, Gkika Eleni, Lange Tim, Ferentinos Konstantinos, Karle Heiko, Brunner Thomas, Wittig Andrea, Nona-Duma Marciana, Blanck Oliver, Krug David
Primary Institution: Universitätsklinikum Schleswig-Holstein - Campus Kiel
Hypothesis
The study aims to assess outcomes after metastasis-directed stereotactic radiotherapy (SRT) in various clinical scenarios for breast cancer patients.
Conclusion
Patients with oligometastatic disease treated for intracranial lesions and metastasis-directed therapy to all sites showed superior overall survival.
Supporting Evidence
- 73% of treated metastases were intracranial lesions.
- Local recurrence rates were significantly higher in intracranial lesions compared to extracranial lesions.
- Patients with oligometastatic disease had superior median progression-free survival compared to those with polymetastatic disease.
- Patients receiving metastasis-directed therapy to all sites had better overall survival than those with selected sites.
- Median overall survival in the whole cohort was 28.4 months.
Takeaway
This study looked at how well a special type of radiation therapy works for breast cancer that has spread to other parts of the body, finding that treating all spots can help patients live longer.
Methodology
An international retrospective cohort study was conducted across thirteen centers, analyzing outcomes such as local recurrence, progression-free survival, and overall survival in breast cancer patients receiving SRT.
Potential Biases
Selection bias may influence outcome differences due to the retrospective nature of the study.
Limitations
The study's retrospective design may lead to incomplete data and follow-up, and the cohort is heterogeneous in terms of patient characteristics and treatment details.
Participant Demographics
The median age at initial diagnosis was 51 years, and 66% of patients had oligometastatic disease.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI (23.4–34.3)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website